Pharma Mirror Magazine

CPhI Report forecasts explosion of contract services growth due to surging INDs and 75 FDA approvals by 2025

March 10, 2021

A post-pandemic pharma report from CPhI predicts the next few years will deliver strong growth in pharma innovation, with oncology and rare

Pharmaceutical News

Syngenta and Botanical Solution Inc. (BSI) team up for a new botanical-based biofungicde rollout !

March 10, 2021

Davis, CA: Botanical Solution Inc. (BSI) and Syngenta, two companies which are closely aligned in their commitment to innovation and sustainability in

Pharma Interest

The drug Fenbendazole can make tumors sensitive to radiotherapy just like agents of chemotherapy

March 8, 2021

Likewise, it was demonstrated by actualizing high throughput screening in-vitro framework that the drug fenbendazole is successful, not just against

Pharmaceutical News

I Holland Announces a New Leadership Team

March 3, 2021

I Holland, leaders in the manufacture of tablet tooling for the pharmaceutical and nutraceutical markets, has announced a series of

Pharmaceutical News

New Drug Approval for in-House Developed Anti-Insomnia Drug Dayvigo (Lemborexant) in Hong Kong

March 2, 2021

Eisai Co., Ltd. announced that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has obtained approval for the in-house-discovered

Pharmaceutical News

Novartis Piqray(R) – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval

March 1, 2021

Novartis announced the Health Sciences Authority (HSA) has approved* Piqray®, an α-specific class I phosphatidylinositol-3-kinase (PIK3CA) inhibitor, for the treatment of

MORE NEWS

CPhI Report forecasts explosion of contract services growth due to surging INDs and 75 FDA approvals by 2025

Syngenta and Botanical Solution Inc. (BSI) team up for a new botanical-based biofungicde rollout !

The drug Fenbendazole can make tumors sensitive to radiotherapy just like agents of chemotherapy

I Holland Announces a New Leadership Team

New Drug Approval for in-House Developed Anti-Insomnia Drug Dayvigo (Lemborexant) in Hong Kong

Novartis Piqray(R) – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval